Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p> There is a gray area where optimism in a research patient in early phase cancer trials crosses over to a misperception of benefit and raises ethical questions about informed consent.</p>

‘Optimistic bias’ may subvert informed consent in early-phase cancer trials

‘Potential harm to patient well-being and autonomy’